The size of the Ovarian Cancer Market in the MEA region is estimated to grow at a sluggish CAGR between 2022 to 2027.
The increasing prevalence of ovarian cancer and the growing use of combination therapies for disease treatment primarily drive the ovarian cancer market in MEA. Ovarian cancer is more common in women between the ages of 55 and 64. The most frequent ovarian cancer symptoms are bloating, pelvic and abdominal discomfort, difficulty eating, and urine symptoms.
In addition, the technological advancements in the healthcare sector are boosting market growth. In addition, the introduction of effective therapies and advanced drugs, and favorable reimbursement policies are driving the market growth.
Other factors such as growing awareness, increasing disposable income, and supportive government policies encourage market growth. Also, the rising initiatives for raising awareness about pre-diagnosing tests and benefits available in the market among people are expected to propel market growth.
Due to the increase in the prevalence of population with growing elderly population especially women over age 50 have higher risk rates of developing ovarian cancer why may due to having any family history of having cancer which is caused due to inherited mutations in the specific genes is the primary cause that is driving the growth in the ovarian cancer market.
With the increase in the new advancement in the technology for developing reliable and efficient tests and therapies for diagnosing cancer in patients, the widely used equipment to test ovarian cancer is the Transvaginal ultrasound (TVUS), which uses high-energy sound waves to identify the presence of abnormalities such as an ovarian tumor. However, other tests are also available in the market which is used for diagnosing and detecting cancer.
The increasing investments by the government and non-government organizations in research and development activities to develop an advanced and effective treatment for cancer and other kinds of disease treatment.
Key players in the region are adopting various market strategies to gain competitiveness overhead the marketplace. The strategies include partnerships, mergers, and acquisitions. Also, these strategies strengthen the regional market expansion.
However, the increase in the availability of various alternative drugs present in the market lack of skilled and trained individuals are also hampering the growth of the ovarian cancer market. Also, due to lack of awareness among the people about the pre-diagnosing effects, lack of proper technology and equipment for diagnosing or detecting early stages are limiting the ovarian cancer market in the MEA region.
This research report on the MEA ovarian cancer market has been segmented and sub-segmented into the following categories:
By Stage of Cancer:
By Cancer Type:
By Type of Treatment:
The Middle East and Africa market is expected to register a moderate share in the global ovarian cancer market during the forecast period. The regional market growth is attributed to the increase in the prevalence of ovarian cancer among the rising geriatric population and increasing healthcare spending. The major growth contributors in the region are South Africa, UAE, and Saudi Arabia.
UAE is expected to witness a significant share in the ovarian cancer market in the coming years. Increasing healthcare expenditure, establishing healthcare facilities, and an aging population is propelling the market growth.
South Africa accounted for the largest share of the Ovarian cancer market. The Proliferation of cancer drives the market growth; according to Globocan, in 2018, around 1,371 new ovarian cancer cases in South Africa, and about 971 people died due to this disease. Also, due to easing age- standardization rate of ovarian cancer is 3.9 per 100,000, as well as increasing initiatives and findings from government and non-government firms in research activities and raising awareness among the people about pre- diagnosing tests and medications available in the market, helps in driving the market growth for ovarian cancer.
KEY MARKET PLAYERS:
Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc., Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]